All Posts

Contact Lenses Market Trends
Contact Lenses: A Comprehensive Guide to Vision Correction and Beyond

Contact lenses have emerged as a groundbreaking innovation within the realm of vision correction, fundamentally reshaping how individuals perceive the world. Serving as an alternative to conventional eyeglasses, contact lenses hold significant value by not only improving visual clarity, but also delivering a natura...

Find More

Pharma News for Gilead, Incannex, Avidity
Eylea HD Injection 8 Mg Approved By FDA; Veopoz Receives FDA Approval for CHAPLE Disease Treatment; FDA Places Second Partial Clinical Hold on AML Enrollment for Magrolimab Trials; FDA Approval to Incannex’s Sleep Apnoea Clinical Trial; FDA Orphan Drug Designation to Avidity’s AOC 1044; Orphan Drug Designation to CanariaBio’s MAb-AR20.5

Eylea HD Injection 8 Mg Approved By FDA for Treatment of Wet AMD, DME, and Diabetic Retinopathy The FDA has approved Regeneron Pharmaceuticals’ EYLEA HD (aflibercept) Injection of 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retin...

Find More

zuranolone-for-postpartum-depression-treatment
Mixed Fortunes for Biogen and Sage’ Zuranolone: Approval Under the Cloud of Rejection

In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting drug zuranolone as the first tablet for postpartum depression on 04 August —but rejected the drug for major depressive disorder treatment. Zurzuvae is a neuroactive steroid that acts as a GABA-A receptor-positive allosteric...

Find More

izervay-for-geographic-atrophy-treatment
Entry of Izervay: First Geographic Atrophy Treatment to Slow Progression

Globally, more than 5 million people are affected by geographic atrophy. Also, as per the published study by the GER group, the global prevalence of geographic atrophy is 0.66% in all ages, but it occurs in 0.34% for 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old. Geographic atrophy is a progressive, i...

Find More

MedTech News for Viseon, ZimVie, Acorai
4WEB Medical’s Cervical Spine Plating Solution; Viseon Launched Visualization System for Minimally Invasive Spine Surgery; ZimVie’s New Mobi-C Implant; GE HealthCare’s Wireless Monitoring Solution; Acorai’s Non-Invasive Intracardiac Pressure Monitor; CytoSorbents’s STAR-T Pivotal Trial

4WEB Medical Launched its Cervical Spine Plating Solution  On August 15, 2023, 4WEB Medical, an orthopedic implant company focused on developing innovative implants that utilize its proprietary Truss Implant Technology™, launched the newest addition to the company's implant portfolio, the Cervical Spine Pla...

Find More

Anti-snoring Devices Market
Exploring the World of Anti-snoring Devices: A Comprehensive Market Assessment

Snoring, a common sleep-related issue, can disrupt both the snorer's sleep and that of their partner or roommate. As per the estimate, about 90 million Americans suffer from snoring, either temporarily or semi-permanently, due to colds, allergies, or other factors. Snoring can have several implications, and it can ...

Find More

Pharma News for Janssen, Galera, Genprex
J&J’s 2-in-1 Tablet for Prostate Cancer; FDA Approves TALVEY for Heavily Pretreated Multiple Myeloma; PDS Biotech Updated on VERSATILE-003 Trial; FDA Issues CRL to NDA for Avasopasem in Radiotherapy-Induced Severe Oral Mucositis in HNC; FDA Orphan Drug Designation to Genprex’s REQORSA; FDA Orphan Drug Designation to Bloomsbury’s BGT-OTCD

FDA Clears J&J’s 2-in-1 Tablet for Prostate Cancer Johnson & Johnson's Janssen Pharmaceutical Companies stated that the US Food and Drug Administration (FDA) had approved AKEEGA (niraparib and abiraterone acetate), the first-and-only dual-action tablet combining a PARP inhibitor including abiraterone ace...

Find More

chronic-spontaneous-urticaria-csu-treatment
Towards a Promising Future: Unveiling Advancements in Chronic Spontaneous Urticaria (CSU) Treatment

Chronic urticarial is a common skin condition characterized by itchy, wheal-and-flare skin reactions or hives. As per Delveinsight analysts, in 2022, there were around 776K individuals in the US affected by chronic urticaria. It can be spontaneous or inducible, lasting more than 6 weeks and persisting for over a ye...

Find More

multiple-myeloma-treatment
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes

Multiple myeloma is the second most prevalent blood cancer diagnosis in the United States, after non-Hodgkin lymphoma. Males are significantly more likely than females to have multiple myeloma. Myeloma incidence is highly tied to age, with older adults having the highest incidence rates and being diagnosed most fre...

Find More

MedTech News for Quest, DuPont, BD
Quest Introduced Consumer-Initiated Blood Test for Alzheimer’s Disease Risk Assessment; DuPont Acquires Spectrum Plastics; BD Received 510(k) Clearance for Molecular Combination Test; Natera Updates on Phase III ALTAIR Trial of Signatera; Anteris’ DurAVR transcatheter heart valve Trial

Quest Introduced First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on Questhealth Website On July 31, 2023, Quest Diagnostics, a leader in diagnostic information services, announced the introduction of the AD-Detect™ Test for Alzheimer's Disease on questhealth.com – the first ...

Find More